Clinical impact of Ocrelizumab dosing delays and their association with CD-19+ B-cell repletion during the COVID-19 pandemic


By Dr Nitin Sahi, Neurology SpR, University Hospitals of North Midlands NHS Trust

Runner-up

This project was awarded runner-up .

View more projects
Poster

Write up

More MS Academy Medication Projects

Safety of Cladribine in people with MS treated in a district general hospital: Audit Report
By Dr Chamila Perera, Senior Clinical Fellow in Neurology, Bedford Hospital NHS Trust
Nabilone, a CB1 agonist, for managing multiple sclerosis symptoms
By Dr Filipa Serrazina, Neurology Resident, Barts Health NHS Trust
Encouraging excellence, developing leaders, inspiring change

MS Academy was established five years ago and in that time has accomplished a huge amount. The six different levels of specialist MS training are dedicated to case-based learning and practical application of cutting edge research. Home to national programme Raising the Bar and the fantastic workstream content it is producing, this is an exciting Academy to belong to.